Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the
last decade, and in many places the demand largely surpasses the capacities of the treatment
centers. Treatment of the disease remains unsatisfactory. All currently used drugs must be
administered parenterally, treatment is lengthy, and adverse drug reactions frequent. There
are currently no drugs that are easily administered and have low toxicity, and might thus be
used as tools to support disease control.
This study aims to compare the safety and efficacy of DB289, a new, orally administered
dication prodrug to pentamidine i.m. injection for the treatment of first stage sleeping
sickness. The project will be executed in the framework of an international consortium
consisting of several partners from academia, industry and from the Democratic Republic of
Congo Ministries of Health.